Pancreatic Cancer Research

ResearcherUniversité Libre de BruxellesActive in the last 2 years

Maria Antonietta Bali

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2697-1329; OpenAlex author ID A5070532539, A5111683458. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
62
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers

Papers 9

  1. Anticipating pancreatic cancer diagnosis through early computerised tomography findings: An ongoing holy quest. First author DOI 10.1002/ueg2.12575↗
  2. Impact of the radiological morphology of the mesopancreas on the outcome after pancreatoduodenectomy for pancreatic ductal adenocarcinoma: retrospective study. Co-author DOI 10.1093/bjsopen/zrae134↗
  3. Development of Clinical Radiomics-Based Models to Predict Survival Outcome in Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study. Last author DOI 10.3390/diagnostics14070712↗
  4. Peritoneal patch in vascular reconstruction during pancreaticoduodenectomy for pancreatic cancer: a single Centre experience. Co-author DOI 10.1080/00015458.2021.1979173↗
  5. Isotoxic High-Dose Stereotactic Body Radiotherapy (iHD-SBRT) Versus Conventional Chemoradiotherapy for Localized Pancreatic Cancer: A Single Cancer Center Eval… Co-author DOI 10.3390/cancers14235730↗
  6. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenoc… Co-author DOI 10.1177/17588359211045860↗
  7. What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact? Co-author DOI 10.1245/s10434-020-09568-2↗
  8. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  9. Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion-weighted MR quantitative parameters and RECIST. Co-author DOI 10.1016/j.ejrad.2018.04.024↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean‐Luc Van Laethem · 8 shared papers, 2018–2024 · strength 1.53
  2. Julie Navez · 5 shared papers, 2021–2024 · strength 0.79
  3. Jean Closset · 5 shared papers, 2021–2024 · strength 0.79
  4. Christelle Bouchart · 5 shared papers, 2021–2024 · strength 0.79
  5. Nicky D’Haene · 2 shared papers, 2023–2024 · strength 0.37
  6. Marie-Lucie Racu · 2 shared papers, 2023–2024 · strength 0.37
  7. Alain Hendlisz · 2 shared papers, 2021–2024 · strength 0.32
  8. Matthieu Hein · 2 shared papers, 2021–2022 · strength 0.26
  9. Ayoub Mokhtari · 1 shared paper, 2024 · strength 0.21
  10. Pieter Demetter · 1 shared paper, 2024 · strength 0.19
  11. Jacques M.E. Deviere · 1 shared paper, 2024 · strength 0.19
  12. Oier Azurmendi Senar · 1 shared paper, 2024 · strength 0.19
  13. Tatjana Arsenijevic · 1 shared paper, 2024 · strength 0.19
  14. Vincent De Pauw · 1 shared paper, 2023 · strength 0.18
  15. Diane Lorenzo · 1 shared paper, 2021 · strength 0.16
  16. Martin Manderlier · 1 shared paper, 2022 · strength 0.15
  17. Raphaël Maréchal · 1 shared paper, 2018 · strength 0.08
  18. Celso Matos · 1 shared paper, 2018 · strength 0.08
  19. Andrew H. Ko · 1 shared paper, 2019 · strength 0.06
  20. Matthew H. G. Katz · 1 shared paper, 2019 · strength 0.06
  21. Christoph Tinchon · 1 shared paper, 2019 · strength 0.06
  22. Stephen John Clarke · 1 shared paper, 2019 · strength 0.06
  23. Jaswinder Singh Samra · 1 shared paper, 2019 · strength 0.06
  24. Kyu‐pyo Kim · 1 shared paper, 2019 · strength 0.06
  25. Martin D. McCarter · 1 shared paper, 2019 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.